•  



ASSOCIATION OF PROGRAMMED CELL DEATH PROTEIN–1 ( PD-1 ) GENE POLYMORPHISM AND SERUM LEVELS OF SOLUBLE PD-1 WITH TYPE 2 DIABETES MELLITUS
قاسم شرهان حرج
Authors : Aya Raed Rasheed1*, Wafaa Ragee1, Qasim S. Al-mayah2
Type 2 diabetes mellitus (T2DM) is a metabolic disorder of multiple etiologies characterized by chronic hyperglycemia with disturbances of fat and protein metabolism resulting from defects in insulin secretion, insulin action or both, and mediated in large part by the alteration in adaptive immunity. This study aimed to evaluate the role of programmed cell death protein – 1 (PD-1) gene polymorphism and serum level of soluble PD-1 in development of T2DM in Iraqi patients. Forty-five T2DM patients were recruited for this study. Other 45 apparently healthy subjects matched for age, gender and ethnic background for patients were also included as control group. Blood samples were collected from each participant, and DNA was extracted from leukocytes. The gene fragment corresponding the PD-1-538 G/A polymorphism was amplified with conventional PCR using specific primers. The genotyping was performed through restriction fragment length gene polymorphism (RFLP). Serum level of soluble PD-1 (sPD-1) was measured by enzyme linked immune sorbent assay (ELISA). There was no significant association between different genotypes of PD-1-538 G/A polymorphism. However, at allelic level, G allele was less frequent among patients than controls (28.89% versus 44.44%) with a significant difference. The median concentration of sPD-1 in patients was 53.12 pg/ml (range 18.24-312.89 pg/ml) compared to 63.83pg//ml (range 16.89-508.65 pg/ml) in controls with no significant difference. Median levels of sPD-1 in patients carrying GG, GA and AA genotypes were 51.67 pg/ml (range 18.24-160.41 pg/mL), 52.77 pg/ml (range 19.32-154.18 pg/mL) and 220.97 pg/ml (range 129.05-312.89 pg/mL) respectively. The GG genotype carriers differed significantly from AA genotype carriers, while there was no significant between AA genotype carriers and AG genotype carriers. These data suggest that A allele of PD-1-538 G/A might be a risk factor for development of T2DM. The GG genotype of this polymorphism associates with higher serum level of sPD-1 than other genotypes.

(FULL ARTICLE LINK) Read more ...
March 2020